Cansortium Texas Acquired by Legacy Therapeutics | Healthcare M&A Deal

Legacy Therapeutics has acquired Cansortium Texas, a substance abuse treatment business in Texas, for $30 million. Legacy Therapeutics acquisitions target Cansortium Texas’s Texas cannabis license and operations, including cultivation, manufacturing, delivery, and Houston retail activities supporting medical marijuana access. The Cansortium Texas acquisition expands Legacy’s healthcare M&A footprint with a platform for Compassionate Use patients in Schulenburg and Houston, aligning with substance abuse treatment acquisition goals. The divestiture acquisition is a strategic acquisition by a strategic buyer, with $25 million payable at closing and $2.5 million due on each of the first and second anniversaries, subject to regulatory approvals and customary closing conditions.